ADMA Biologics Inc Can’t Be More Risky. Trades Sigfnicicantly Lower

The stock of ADMA Biologics Inc (NASDAQ:ADMA) is a huge mover today! The stock decreased 14.71% or $1.19 on April 7, hitting $6.9. ADMA Biologics Inc (NASDAQ:ADMA) has declined 23.50% since September 1, 2015 and is downtrending. It has underperformed by 30.19% the S&P500. The move comes after 7 months negative chart setup for the $73.74 million company. It was reported on Apr, 8 by We have $6.14 PT which if reached, will make NASDAQ:ADMA worth $8.11 million less.

Out of 4 analysts covering ADMA Biologics (NASDAQ:ADMA), 6 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. ADMA Biologics was the topic in 2 analyst reports since September 9, 2015 according to StockzIntelligence Inc. Maxim Group maintained the stock on September 17 with “Buy” rating.

According to Zacks Investment Research, “ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.”

The institutional sentiment increased to 2.6 in Q3 2015. Its up 0.20, from 2.4 in 2015Q2. The ratio increased, as 3 funds sold all ADMA Biologics Inc shares owned while 2 reduced positions. 4 funds bought stakes while 9 increased positions. They now own 9.34 million shares or 34.43% more from 6.95 million shares in 2015Q2.

Aisling Capital Llc holds 5.3% of its portfolio in ADMA Biologics Inc for 3.61 million shares. Consonance Capital Management Lp owns 1.05 million shares or 1.24% of their US portfolio. Moreover, Broadfin Capital Llc has 0.45% invested in the company for 964,193 shares. The New York-based J. Goldman & Co Lp has invested 0.09% in the stock. Weiss Multi, a Alabama-based fund reported 154,000 shares.

ADMA Biologics Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with’s FREE daily email newsletter.

Add Comment